Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Shares in British meat producer Cranswick slumped about 9% on Monday after UK supermarkets suspended supplies from one of its ...

Houston-based Empower Pharmacy has repeatedly been admonished by the FDA for failing to follow federal rules that ensure drug ...

Tesla Shares in electric vehicle maker Tesla have climbed back to their highest point since February, amid investor optimism ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

The price you pay for Zepbound may depend on factors such as your dosage, whether you have health insurance, your location, and the pharmacy you use. Financial assistance may be available to help ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...